Australia's ACMS backs EllaOne advertising

22 May 2017 - Deborah Wilkes

Archived

Consumer advertising for the emergency contraceptive ulipristal – the active ingredient of HRA Pharma's EllaOne – will be allowed in Australia from 1 February 2018, if a decision by the country's Advisory Committee on Medicines Scheduling (ACMS) is implemented.

Click tags below for more information on topics:

TGA HRA Pharma

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: